Lewy body dementia
Resources for Patients and Caregivers
Lewy body dementia (LBD) is a disease associated with abnormal deposits of a protein called alpha-synuclein in the brain. These deposits, called Lewy bodies, affect chemicals in the brain whose changes, in turn, can lead to problems with thinking, movement, behavior, and mood.
Cluster Number:
Wiki Number: 26-Lewy Bodies Disorder/Dementia
Diagnosis:
US Patients: American actor and comedian Robin Williams committed suicide in 2014 with Parkinson’s and Lewy Bodies.
World Patients:
Sex Ratio:
Age Onset: after age 50 with life expectancy of 8 years after diagnosis
Brain Area: The SNCA gene encodes the alpha-synuclein protein which is a building-block of Lewy bodies.
Symptoms: acting out dreams, visual hallucinations, attention difficulties, slowness of movements
Progression: dementia and Parkinson’s patients may also be affected. Cause cognitive fluctuations.
Causes: clumps of protein form on brain neurons causing heart and digestive functions, low blood pressure and apathy.
Medications: several
Therapies: Cognitive training, deep-brain and transcranial direct current stimulations have been used.
Youtube Video: Lewy Body Disease
Amazon or Library Book:
A Caregiver’s Guide to Lewy Body Dementia
Click the book to link or buy from Amazon.
Support Group: lbda.org; 800-539-9767 (lewybodydementiaassociation)
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Cognitive decline profiles associated with lewy pathology in the context of Alzheimer's disease neuropathologic changeby Jon B Toledo on December 20, 2024
CONCLUSIONS: LP and ADNC differentially affected cross-sectional and longitudinal cognitive profiles in a large autopsy sample. Concomitant Braak V-VI neurofibrillary tangle pathology had a strong impact on clinical progression in those with LP, regardless of the initial stage. Thus, LB and ADNC co-pathology interact to affect cognitive domains that may be used to track Lewy Body disease longitudinally and as outcome measures in therapeutic trials.
- Manipulated mesenchymal stem cell therapy in the treatment of Parkinson's diseaseby Seyedeh Toktam Ekrani on December 19, 2024
Mesenchymal stem cell (MSC) therapy has been considered a promising approach for the treatment of Parkinson's disease (PD) for several years. PD is a globally prevalent neurodegenerative disease characterized by the accumulation of Lewy bodies and the loss of dopaminergic neurons, leading to severe motor and non-motor complications in patients. As current treatments are unable to halt the progression of neuronal loss and dopamine degradation, MSC therapy has emerged as a highly promising...
- Dementia with lewy bodies patients with high tau levels display unique proteome profilesby Sinead Greally on December 19, 2024
CONCLUSION: This molecular-level data supports the idea of neurodegenerative disease as a continuum of diseases with distinct PTM profiles DLBTau^(+) and DLBTau^(-) patients in comparison to AD. These findings further emphasize the importance of identifying specific and tailored therapeutic approaches targeting the involved proteopathies in the neurodegenerative disease spectrum.
- Assessment of cerebral perfusion alterations in dementia with Lewy bodies and Alzheimer's diseaseby Yanlai Xia on December 19, 2024
CONCLUSIONS: DLB demonstrates a different pattern of regional blood flow reduction and prolonged ATT, which is different from that in AD. ASL-derived parameters provide critical discriminative information for differentiating DLB and AD.